metformin and bibw 2992

metformin has been researched along with bibw 2992 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (100.00)	2.80

Authors

Authors	Studies
Chang, YL; Chen, YM; Chou, YC; He, CH; Hsu, CC; Huang, TY; Su, VY; Yang, KY; Yen, JC	1
Li, G; Lin, Z; Mei, J; Xu, X	1

Other Studies

2 other study(ies) available for metformin and bibw 2992

Article	Year
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer. Scientific reports, 2020, 09-11, Volume: 10, Issue:1 Topics: Afatinib; Aged; Aged, 80 and over; Antacids; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Male; Metformin; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Steroids; Treatment Failure	2020
Does metformin improve the efficacy of standard epidermal growth factor receptor-tyrosine kinase inhibitor treatment for patients with advanced non-small-cell lung cancer? Interactive cardiovascular and thoracic surgery, 2021, 01-01, Volume: 32, Issue:1 Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Male; Metformin; Middle Aged; Mutation; Protein Kinase Inhibitors	2021

Article

Year

The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.

Scientific reports, 2020, 09-11, Volume: 10, Issue:1

Topics: Afatinib; Aged; Aged, 80 and over; Antacids; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Male; Metformin; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Steroids; Treatment Failure

2020

Does metformin improve the efficacy of standard epidermal growth factor receptor-tyrosine kinase inhibitor treatment for patients with advanced non-small-cell lung cancer?

Interactive cardiovascular and thoracic surgery, 2021, 01-01, Volume: 32, Issue:1

Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Male; Metformin; Middle Aged; Mutation; Protein Kinase Inhibitors

2021